Literature DB >> 8848531

Caffeine attenuates scopolamine-induced memory impairment in humans.

W Riedel1, E Hogervorst, R Leboux, F Verhey, H van Praag, J Jolles.   

Abstract

Caffeine consumption can be beneficial for cognitive functioning. Although caffeine is widely recognized as a mild CNS stimulant drug, the most important consequence of its adenosine antagonism is cholinergic stimulation, which might lead to improvement of higher cognitive functions, particularly memory. In this study, the scopolamine model of amnesia was used to test the cholinergic effects of caffeine, administered as three cups of coffee. Subjects were 16 healthy volunteers who received 250 mg caffeine and 2 mg nicotine separately, in a placebo-controlled double-blind cross-over design. Compared to placebo, nicotine attenuated the scopolamine-induced impairment of storage in short-term memory and attenuated the scopolamine-induced slowing of speed of short-term memory scanning. Nicotine also attenuated the scopolamine-induced slowing of reaction time in a response competition task. Caffeine attenuated the scopolamine-induced impairment of free recall from short- and long-term memory, quality and speed of retrieval from long-term memory in a word learning task, and other cognitive and non-cognitive measures, such as perceptual sensitivity in visual search, reading speed, and rate of finger-tapping. On the basis of these results it was concluded that caffeine possesses cholinergic cognition enhancing properties. Caffeine could be used as a control drug in studies using the scopolamine paradigm and possibly also in other experimental studies of cognitive enhancers, as the effects of a newly developed cognition enhancing drug should at least be superior to the effects of three cups of coffee.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8848531     DOI: 10.1007/bf02246090

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  19 in total

1.  The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers.

Authors:  K Wesnes; R Anand; P Simpson; L Christmas
Journal:  J Psychopharmacol       Date:  1990-01       Impact factor: 4.153

2.  Distinguishing between attentional and amnestic effects in information processing: the separate and combined effects of scopolamine and nicotine on verbal free recall.

Authors:  J Rusted; P Eaton-Williams
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  TRH attenuates scopolamine-induced memory impairment in humans.

Authors:  S E Molchan; A M Mellow; B A Lawlor; H J Weingartner; R M Cohen; M R Cohen; T Sunderland
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  The effects of scopolamine on working memory in healthy young volunteers.

Authors:  J M Rusted; D M Warburton
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  The effects of age on the response to caffeine.

Authors:  C G Swift; B Tiplady
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

6.  The effects of low doses of caffeine on human performance and mood.

Authors:  H R Lieberman; R J Wurtman; G G Emde; C Roberts; I L Coviella
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

7.  Effects of acute doses of oxiracetam in the scopolamine model of human amnesia.

Authors:  L Preda; M Alberoni; S Bressi; C Cattaneo; J Parini; N Canal; M Franceschi
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Nicotinic systems and cognitive function.

Authors:  E D Levin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  Effects of caffeine on mood and memory.

Authors:  W H Loke
Journal:  Physiol Behav       Date:  1988

10.  Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum.

Authors:  N L Benowitz; H Porchet; L Sheiner; P Jacob
Journal:  Clin Pharmacol Ther       Date:  1988-07       Impact factor: 6.875

View more
  29 in total

Review 1.  The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities.

Authors:  Claudio Da Cunha; Miriam Elizabeth Mendes Angelucci; Newton S Canteras; Susan Wonnacott; Reinaldo N Takahashi
Journal:  Cell Mol Neurobiol       Date:  2002-06       Impact factor: 5.046

Review 2.  Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.

Authors:  L Lyon; L M Saksida; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2011-11-10       Impact factor: 4.530

Review 3.  Ethnobotany as a pharmacological research tool and recent developments in CNS-active natural products from ethnobotanical sources.

Authors:  Will C McClatchey; Gail B Mahady; Bradley C Bennett; Laura Shiels; Valentina Savo
Journal:  Pharmacol Ther       Date:  2009-05-05       Impact factor: 12.310

4.  Adenosine A(2A) receptors are necessary and sufficient to trigger memory impairment in adult mice.

Authors:  N Pagnussat; A S Almeida; D M Marques; F Nunes; G C Chenet; P H S Botton; S Mioranzza; C M Loss; R A Cunha; L O Porciúncula
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

Review 5.  Approaches to measuring the effects of wake-promoting drugs: a focus on cognitive function.

Authors:  Christopher J Edgar; Edward F Pace-Schott; Keith A Wesnes
Journal:  Hum Psychopharmacol       Date:  2009-07       Impact factor: 1.672

Review 6.  Cognition enhancers in age-related cognitive decline.

Authors:  W J Riedel; J Jolles
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

Review 7.  [Neuroenhancement].

Authors:  G Gründer; T Bartsch
Journal:  Nervenarzt       Date:  2014-12       Impact factor: 1.214

8.  Chronic caffeine treatment prevents sleep deprivation-induced impairment of cognitive function and synaptic plasticity.

Authors:  Ibrahim A Alhaider; Abdulaziz M Aleisa; Trinh T Tran; Karem H Alzoubi; Karim A Alkadhi
Journal:  Sleep       Date:  2010-04       Impact factor: 5.849

9.  The role of adenosine in Alzheimer's disease.

Authors:  Anisur Rahman
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

10.  Caffeine and alcohol intakes and overall nutrient adequacy are associated with longitudinal cognitive performance among U.S. adults.

Authors:  May A Beydoun; Alyssa A Gamaldo; Hind A Beydoun; Toshiko Tanaka; Katherine L Tucker; Sameera A Talegawkar; Luigi Ferrucci; Alan B Zonderman
Journal:  J Nutr       Date:  2014-04-17       Impact factor: 4.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.